Long noncoding RNA in prostate, bladder, and kidney cancer - PubMed (original) (raw)
Review
. 2014 Jun;65(6):1140-51.
doi: 10.1016/j.eururo.2013.12.003. Epub 2013 Dec 14.
Affiliations
- PMID: 24373479
- DOI: 10.1016/j.eururo.2013.12.003
Review
Long noncoding RNA in prostate, bladder, and kidney cancer
Elena S Martens-Uzunova et al. Eur Urol. 2014 Jun.
Abstract
Context: Genomic regions without protein-coding potential give rise to millions of protein-noncoding RNA transcripts (noncoding RNA) that participate in virtually all cellular processes. Research over the last 10 yr has accumulated evidence that long noncoding RNAs (lncRNAs) are often altered in human urologic cancers.
Objective: To review current progress in the biology and implication of lncRNAs associated with prostate, bladder, and kidney cancer.
Evidence acquisition: The PubMed database was searched for articles in the English language with combinations of the Medical Subject Headings terms long non coding RNA, long noncoding RNA, long untranslated RNA, cancer, neoplasms, prostate, bladder, and kidney.
Evidence synthesis: We summarise existing knowledge on the systematics, biology, and function of lncRNAs, particularly these involved in prostate, kidney, and bladder cancer. We also discuss the possible utilisation of lncRNAs as novel biomarkers and potential therapeutic targets in urologic malignancies and portray the major challenges and future perspectives of ongoing lncRNA research.
Conclusions: LncRNAs are important regulators of gene expression interacting with the major pathways of cell growth, proliferation, differentiation, and survival. Alterations in the function of lncRNAs promote tumour formation, progression, and metastasis of prostate, bladder, and kidney cancer. LncRNAs can be used as noninvasive tumour markers in urologic malignancies. Increased knowledge of the molecular mechanisms by which lncRNAs perform their function in the normal and malignant cell will lead to a better understanding of tumour biology and could provide novel therapeutic targets for the treatment of urologic cancers.
Patient summary: In this paper we reviewed current knowledge of long noncoding RNAs (lncRNAs) for the detection and treatment of urologic cancers. We conclude that lncRNAs can be used as novel biomarkers in prostate, kidney, or bladder cancer. LncRNAs hold promise as future therapeutic targets, but more research is needed to gain a better understanding of their biologic function.
Keywords: Beckwith-Wiedemann syndrome; Bladder cancer; Kidney cancer; Long noncoding RNA; Prostate cancer; Renal cell carcinoma; Urothelial carcinoma; Wilms tumour; lncRNA.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
- Long noncoding RNA: "LNCs" to cancer.
Sültmann H, Diederichs S. Sültmann H, et al. Eur Urol. 2014 Jun;65(6):1152-3. doi: 10.1016/j.eururo.2014.01.032. Epub 2014 Jan 31. Eur Urol. 2014. PMID: 24508069 No abstract available.
Similar articles
- Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ. Mouraviev V, et al. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):14-20. doi: 10.1038/pcan.2015.48. Epub 2015 Oct 27. Prostate Cancer Prostatic Dis. 2016. PMID: 26503110 Review. - Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers.
Terracciano D, Ferro M, Terreri S, Lucarelli G, D'Elia C, Musi G, de Cobelli O, Mirone V, Cimmino A. Terracciano D, et al. Transl Res. 2017 Jun;184:108-117. doi: 10.1016/j.trsl.2017.03.005. Epub 2017 Apr 7. Transl Res. 2017. PMID: 28438520 Review. - The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
Ramnarine VR, Kobelev M, Gibb EA, Nouri M, Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A, Collins CC. Ramnarine VR, et al. Eur Urol. 2019 Nov;76(5):546-559. doi: 10.1016/j.eururo.2019.07.040. Epub 2019 Aug 22. Eur Urol. 2019. PMID: 31445843 Review. - Identification of differentially expressed long noncoding RNAs in bladder cancer.
Peter S, Borkowska E, Drayton RM, Rakhit CP, Noon A, Chen W, Catto JW. Peter S, et al. Clin Cancer Res. 2014 Oct 15;20(20):5311-21. doi: 10.1158/1078-0432.CCR-14-0706. Epub 2014 Aug 27. Clin Cancer Res. 2014. PMID: 25165097 - Comprehensive Characterization of Common and Cancer-Specific Differently Expressed lncRNAs in Urologic Cancers.
Yan YJ, Zhang L, Zhou JJ, Chen ZJ, Liao YX, Zeng JM, Shen H. Yan YJ, et al. Comput Math Methods Med. 2021 Jul 9;2021:5515218. doi: 10.1155/2021/5515218. eCollection 2021. Comput Math Methods Med. 2021. PMID: 34335862 Free PMC article.
Cited by
- Silencing LINC01021 inhibits gastric cancer through upregulation of KISS1 expression by blocking CDK2-dependent phosphorylation of CDX2.
Wang Y, Jiang R, Wang Q, Li Y, Sun Z, Zhao H. Wang Y, et al. Mol Ther Nucleic Acids. 2021 Jan 26;24:832-844. doi: 10.1016/j.omtn.2021.01.025. eCollection 2021 Jun 4. Mol Ther Nucleic Acids. 2021. PMID: 34026327 Free PMC article. - The long noncoding RNA TINCR promotes breast cancer cell proliferation and migration by regulating OAS1.
Lu D, Di S, Zhuo S, Zhou L, Bai R, Ma T, Zou Z, Chen C, Sun M, Tang J, Zhang Z. Lu D, et al. Cell Death Discov. 2021 Mar 1;7(1):41. doi: 10.1038/s41420-021-00419-x. Cell Death Discov. 2021. PMID: 33649294 Free PMC article. - Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer.
Wan X, Huang W, Yang S, Zhang Y, Pu H, Fu F, Huang Y, Wu H, Li T, Li Y. Wan X, et al. Oncotarget. 2016 Sep 13;7(37):60503-60518. doi: 10.18632/oncotarget.11391. Oncotarget. 2016. PMID: 27556357 Free PMC article. - OIP5-AS1 contributes to tumorigenesis in hepatocellular carcinoma by miR-300/YY1-activated WNT pathway.
Wang Y, Dou L, Qin Y, Yang H, Yan P. Wang Y, et al. Cancer Cell Int. 2020 Sep 9;20:440. doi: 10.1186/s12935-020-01467-6. eCollection 2020. Cancer Cell Int. 2020. PMID: 32943988 Free PMC article. - Long non-coding RNA-H19 antagonism protects against renal fibrosis.
Xie H, Xue JD, Chao F, Jin YF, Fu Q. Xie H, et al. Oncotarget. 2016 Aug 9;7(32):51473-51481. doi: 10.18632/oncotarget.10444. Oncotarget. 2016. PMID: 27391349 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical